Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Zevra Therapeutics a consensus "Moderate Buy" rating (7 buys, 2 holds) with an average 12‑month price target of $23, well above the recent share price around $10.32.
• Company insiders have sold a total of 114,158 shares (≈$1.06M) in the past three months, leaving insiders with about 2.40% ownership, which may be viewed as a cautionary signal by investors.
• Zevra's clinical pipeline includes lead candidate KP1077 in Phase 2 for idiopathic hypersomnia, KP1077N in Phase 1/2 for narcolepsy, and Celiprolol in Phase 1/2 for vascular Ehlers‑Danlos syndrome.

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $23.00.

ZVRA has been the topic of a number of recent analyst reports. BTIG Research assumed coverage on Zevra Therapeutics in a report on Monday, March 16th. They issued a "buy" rating and a $23.00 price objective on the stock. Guggenheim set a $23.00 target price on Zevra Therapeutics and gave the stock a "buy" rating in a research note on Tuesday, March 10th. HC Wainwright set a $26.00 target price on Zevra Therapeutics in a research report on Tuesday, December 30th. Weiss Ratings raised Zevra Therapeutics from a "sell (d+)" rating to a "hold (c+)" rating in a research note on Tuesday, March 10th. Finally, Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, April 11th.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $10.32 on Thursday. The company's 50-day moving average is $9.23 and its two-hundred day moving average is $9.26. Zevra Therapeutics has a 1-year low of $6.77 and a 1-year high of $13.16. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.68 and a quick ratio of 5.63. The firm has a market capitalization of $605.89 million, a price-to-earnings ratio of 7.76 and a beta of 0.89.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, insider Joshua Schafer sold 10,500 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $9.19, for a total transaction of $96,495.00. Following the completion of the transaction, the insider owned 62,278 shares of the company's stock, valued at $572,334.82. This trade represents a 14.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Timothy J. Sangiovanni sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total transaction of $27,540.00. Following the completion of the sale, the senior vice president directly owned 29,590 shares in the company, valued at $271,636.20. This trade represents a 9.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 114,158 shares of company stock worth $1,062,878. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ZVRA. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of Zevra Therapeutics in the 4th quarter valued at $53,000. DGS Capital Management LLC purchased a new position in Zevra Therapeutics during the 4th quarter valued at about $133,000. Millennium Management LLC boosted its holdings in Zevra Therapeutics by 9.6% during the 4th quarter. Millennium Management LLC now owns 1,134,358 shares of the company's stock valued at $10,164,000 after acquiring an additional 99,107 shares during the period. Man Group plc grew its position in Zevra Therapeutics by 174.4% in the 4th quarter. Man Group plc now owns 92,347 shares of the company's stock valued at $827,000 after acquiring an additional 58,695 shares in the last quarter. Finally, Engineers Gate Manager LP increased its stake in Zevra Therapeutics by 23.4% during the fourth quarter. Engineers Gate Manager LP now owns 44,020 shares of the company's stock worth $394,000 after purchasing an additional 8,359 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.